Supplementary Tables 1-6 from Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry
Blanca EspinetAna FerrerBeatríz BellosilloLara NonellAntonio SalarConcepción Fernández‐RodríguezEulàlia PuigdecanetJavier GimenoM. García GarcíaMaria Carmen VelaElisa LuñoRosa ColladoJosé‐Tomás NavarroEsmeralda de la BandaPau AbrisquetaLeonor ArenillasCristina SerranoJosep LloretaBelén MiñanaAndrea CeruttiLourdes FlorensaAlberto ÓrfãoFerrán SanzFrançesc SoléDavid Dominguez-SolaSérgio Serrano
0
Citation
0
Reference
10
Related Paper
Abstract:
<p>PDF file 233K, SupplementaryTable S1. Detailed clinical and pathological features of all the cases included in the study; S2. Detailed flow cytometric, cytogenetic and molecular findings of all the cases included in the study; S3. Sequence analysis of the MTC PCR products encompassing the IGH/CCND1 junction; S4. List of differentially expressed genes between MCL and MALD1 with order of appearance in Figure 4C; S5. Summary of the main pathways differentially enriched in MALD1 and MCL lymphocytes; S6. Table of all samplesused to generatethe CART. Classification column presents the assigned group after applying the CART</p>Keywords:
Lymphocytosis
Cite
Citations (1)
Objective To investigate the feasibility of detecting cyclin D1 mRNA in paraffin-embedded tissues by reverse transcriptase polymerase chain reaction (RT-PCR) and competitive RT-PCR and its diagnostic and differential diagnostic significance for mantle cell lymphoma (MCL). Methods(Paraffin-embedded) samples of 36 cases of MCL, 71 cases of other small B-cell lymphomas and 20 cases of lymphoid reactive hyperplasia as control group were retrieved from archival materials. Cyclin D1 protein and its mRNA was detected by EnVision and RT-PCR and competitive RT-PCR in all samples. House-keeping gene PGK was choosen as internal control. Results (1) Cyclin D1 protein was expressed in 27 of the 38 MCL (71.1%). No cyclin D1 expression was found in the control group. (2) PGK was detected in 103 of the 116 cases (88.8%) and also detected in 34 of 36 MCL cases (94.7%). (3) cyclin D1 mRNA was detected in 34 nodal mantle cell lymphoma cases by RT-PCR in paraffin-embedded tissues. The positive rate of cyclin D1 mRNA was 94.4% in mantle cell lymphomas after exclusion of the 2 cases which were negative for both cyclin D1 mRNA and PGK. cyclin D1 mRNA was not detected in other nodal small B-cell lymphomas or lymphoid reactive hyperplasia, except 1 case of B-SLL. Sequencing analysis showed that sequences were identical to cyclin D1. (4) Cyclin D1 mRNA overexpression was detected in 27 cases of nodal mantle cell lymphoma by competitive RT-PCR in paraffin-embedded tissues. The positive rate of cyclin D1 mRNA overexpression was 75.0% in mantle cell lymphomas after exclusion of 2 cases which were negative for both cyclin D1 mRNA and PGK. cyclin D1 mRNA overexpression was not detected in other nodal small B-cell lymphomas or lymphoid reactive hyperplasia. Conclusion RT-PCR and competitive RT-PCR detection of cyclin D1 mRNA overexpression could be used for the diagnosis and differential diagnosis of mantle cell lymphoma in paraffin-embedded blocks.
Cite
Citations (0)
Background Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other small B-cell lymphomas. The clinical and pathological characteristics of patients with this form of lymphoma have not been well defined. Overexpression of the transcription factor SOX11 has been observed in conventional mantle cell lymphoma. The aim of this study was to determine whether this gene is expressed in cyclin D1-negative mantle cell lymphoma and whether its detection may be useful to identify these tumors.Design and Methods The microarray database of 238 mature B-cell neoplasms was re-examined. SOX11 protein expression was investigated immunohistochemically in 12 cases of cyclin D1-negative mantle cell lymphoma, 54 cases of conventional mantle cell lymphoma, and 209 additional lymphoid neoplasms.Results SOX11 mRNA was highly expressed in conventional and cyclin D1-negative mantle cell lymphoma and in 33% of the cases of Burkitt’s lymphoma but not in any other mature lymphoid neoplasm. SOX11 nuclear protein was detected in 50 cases (93%) of conventional mantle cell lymphoma and also in the 12 cyclin D1-negative cases of mantle cell lymphoma, the six cases of lymphoblastic lymphomas, in two of eight cases of Burkitt’s lymphoma, and in two of three T-prolymphocytic leukemias but was negative in the remaining lymphoid neoplasms. Cyclin D2 and D3 mRNA levels were significantly higher in cyclin D1-negative mantle cell lymphoma than in conventional mantle cell lymphoma but the protein expression was not discriminative. The clinico-pathological features and outcomes of the patients with cyclin D1-negative mantle cell lymphoma identified by SOX11 expression were similar to those of patients with conventional mantle cell lymphoma.Conclusions SOX11 mRNA and nuclear protein expression is a highly specific marker for both cyclin D1-positive and negative mantle cell lymphoma.
BCL10
Cyclin D2
Cite
Citations (379)
Histopathology
Cite
Citations (43)
Hematopathology
Immunophenotyping
Cite
Citations (71)
Mantle cell lymphoma is characterized by a genetic translocation results in aberrant overexpression of the CCND1 gene, which encodes cyclin D1. This protein functions as a regulator of the cell cycle progression, hence is considered to play an important role in the pathogenesis of the disease. In this study, we used RNA interference strategies to examine whether cyclin D1 might serve as a therapeutic target for mantle cell lymphoma. Knocking down cyclin D1 resulted in significant growth retardation, cell cycle arrest, and most importantly, induction of apoptosis. These results mark cyclin D1 as a target for mantle cell lymphoma and emphasize the therapeutic potential hidden in its silencing.
Cyclin B
Cyclin D
Cyclin A2
Cyclin D2
Cite
Citations (27)
The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies
Cyclin B
Cyclin D
Cite
Citations (20)
Meeting abstracts Cyclin D1, an important component of cell cycle and a protein with known oncogenic potential, is over expressed in mantle cell lymphoma (MCL). MCL is a distinct clinical pathologic subtype of B cell non-Hodgkin's lymphoma often associated with poor prognosis. New therapeutic
Cite
Citations (0)
OBJECTIVE: To observe the expression of cyclin D1 and explore its clinical significance in small cell lymphoma. METHODS: Immunohistochemical method was used to detect the expression of CD20, CD45RO and cyclin D1 in 31 formalin- fixed and paraffin-embedded tissue samples of human small cell lymphomas. RESULTS: Twenty-eight cases were categorized into B cell lymphoma and 3 into T cell lymphoma. Only 5 cases of B cell lymphoma had cyclin D1 expression (17.86%) that did not significantly differ between nodal and extranodal lymphomas (P>0.05), indicating the presence of mantle cell lymphoma. CONCLUSION: The overexpression of cyclin D1 is a highly characteristic and specific indicator that discriminates mantle cell lymphoma from other small cell lymphomas, and this protein may offer critial guidance for therapeutic protocol and prognostic estimation.
Cite
Citations (1)
Cyclin D1 (CCND1) protein overexpression and/or the t(11;14)(q13;q32) translocation are the pathognomonic hallmarks of mantle cell lymphoma (MCL). However, there have been cases that lacked both t(11;14) and cyclin D1 protein but still had a gene expression profile suggesting a diagnosis of MCL. SOX11 expression was detected in most cyclin D1- negative MCL and can serve as a specific biomarker for the diagnosis of this subset of MCL. Lack of SOX11 expression in MCL was associated with an indolent subset and favorable prognosis.
Cyclin D
Pathognomonic
Cyclin B
Cite
Citations (32)